

AGENDA

Translational Advances in Cancer Prevention Agent Development
*Sponsored by the Division of Cancer Prevention, National Cancer Institute
and the Office of Disease Prevention
National Institutes of Health
Bethesda, MD 20892
DATE: August 27-29, 2020*

Day 1 Morning Session (8:00 to 12:00)

- 7:00-8:00 AM **Registration** (Please allow sufficient time to go through security)
- 8:00-8:30 AM **Welcome Remarks**

Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI
Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI
- 8:30-9:30 AM **Translational Research Plenary Speaker**
Raymond DuBois, M.D., Ph.D., Medical University of South Carolina
*Inflammation and inflammatory mediators as targets for cancer
prevention/interception*

Session I*

Advances in Small Molecule Agent Development

Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.

- 9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center

Estrogen metabolism: A target for intervention in non-small cell lung cancer
- 10:00-10:30 AM Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center

Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters
- 10:30-10:50 AM Break**
- 10:50-11:20 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio

Cancer and aging prevention by mTOR inhibition
- 11:20-11:50 AM Speaker 4: Karen Liby, Ph.D., Michigan State University

Targeting the immune system for the prevention of Kras-driven cancers
- 11:50-1:15 PM Lunch**

*Session talks will be 25 min with 5 min Q&A

Day 1 Afternoon Session (1:15 to 4:30)

Session II

Advances in Immunomodulatory Agent Development

Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.

- 1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota
A STAT3 decoy for lung cancer prevention
- 1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School
Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial
- 2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia
CD137 immune checkpoint pathway as an effective target for cancer immunoprevention
- 2:45-3:00 PM Break
- 3:00-3:30 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital
Epithelium-derived alarmins role in breast cancer immunoprevention
- 3:30-3:50 PM **NCI PREVENT Preclinical Drug Development Program**
Mark Miller, Ph.D., Division of Cancer Prevention, NCI
- Q&A Session until 4:30 PM

4:30-6:00 PM Poster Session

Day 2 Morning Session (9:00 to 12:00)

Session III

Alternative Dosing and Combination Strategies to Reduce Toxicity

Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.

- 9:00-9:30 AM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center
Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer
- 9:30-10:00 AM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University
Location, location, location: oral cancer chemoprevention by local delivery
- 10:00-10:30 AM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma
Safer chemopreventive approaches to colonic adenoma prevention
- 10:30-10:45 AM Break**
- 10:45-11:15 AM Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics
Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427
- 11:15-11:45 AM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center
Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP
- 11:45-1:00 PM Lunch**

Day 2 Afternoon Session (1:00 to 4:00)

Session IV

Emerging Vaccines for Cancer Prevention

Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.

- | | |
|---------------------|---|
| 1:00-1:30 PM | Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University
<i>Immunoprevention for Lynch Syndrome</i> |
| 1:30-2:00 PM | Speaker 2: Mary (Nora) Disis, M.D., University of Washington
<i>Vaccines targeting cancer initiation associated proteins</i> |
| 2:00-2:30 PM | Speaker 3: Richard Roden, Ph.D., Johns Hopkins University
<i>Development of vaccines for broad protection against and elimination of HPV infection</i> |
| 2:30-2:50 PM | Break |
| 2:50-3:20 PM | Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh
<i>MUC1 vaccine for prevention of colorectal adenoma</i> |
| 3:20-3:50 PM | Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center
<i>Development of a Kras preventive vaccine</i> |
| 4:00-6:00 PM | Poster Session |

Day 3 Morning Session (8:00 to 12:00)

8:00-9:00 AM

Clinical Research Plenary Speaker

Powel Brown, M.D., Ph.D., MD Anderson Cancer Center
Novel cancer prevention strategies in the molecular era

Session V

Cancer Prevention Clinical Trials

Co-Chairs: Peter Allen and Eva Szabo

9:00-9:15 AM

Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)

Eva Szabo, M.D., Division of Cancer Prevention, NCI

Q&A to 9:30 AM

9:30-10:00 AM

Speaker 1: Peter Allen, M.D., Duke University

Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?

10:00-10:30 AM

Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

Cancer immune-interception for Lynch Syndrome

10:30-10:50 AM

Break

10:50-11:20 AM

Speaker 3: Seema Khan, M.D., Northwestern University

Local transdermal drug delivery to the breast for cancer prevention

11:20-11:50 AM

Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

Novel strategies for aspirin prevention of cancer

12:00 PM

Adjourn